Drug Inhibition of SARS-CoV-2 Replication in Human Pluripotent Stem Cell–Derived Intestinal Organoids

Zhu, 2020, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med, 382, 727, 10.1056/NEJMoa2001017 Wei, 2020, Diarrhea is associated with prolonged symptoms and viral carriage in COVID-19, Clin Gastroenterol Hepatol, 18, 1753, 10.1016/j.cgh.2020.04.030 Luo, 2020, Don't overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19), Clin Gastroenterol Hepatol, 18, 1636, 10.1016/j.cgh.2020.03.043 Wang, 2020, Pancreatic injury patterns in patients with coronavirus disease 19 pneumonia, Gastroenterology, 159, 367, 10.1053/j.gastro.2020.03.055 Xiao, 2020, Evidence for gastrointestinal infection of SARS-CoV-2, Gastroenterology, 158, 1831, 10.1053/j.gastro.2020.02.055 Xu, 2020, Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding, Nat Med, 26, 502, 10.1038/s41591-020-0817-4 Wu, 2020, Prolonged presence of SARS-CoV-2 viral RNA in faecal samples, Lancet Gastroenterol Hepatol, 5, 434, 10.1016/S2468-1253(20)30083-2 Lai, 2020, Extra-respiratory manifestations of COVID-19, Int J Antimicrob Agents, 56, 106024, 10.1016/j.ijantimicag.2020.106024 Gupta, 2020, Extrapulmonary manifestations of COVID-19, Nat Med, 26, 1017, 10.1038/s41591-020-0968-3 Hoffmann, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052 Puelles, 2020, Multiorgan and renal tropism of SARS-CoV-2, N Engl J Med, 383, 590, 10.1056/NEJMc2011400 Liebau, 2019, Stem cell derived organoids in human disease and development, Stem Cells Int, 2019, 7919427, 10.1155/2019/7919427 Hohwieler, 2016, “Miniguts” from plucked human hair meet Crohn’s disease, Z Gastroenterol, 54, 748 Huang, 2020, PDX-derived organoids model in vivo drug response and secrete biomarkers, JCI Insight, 5, 135544, 10.1172/jci.insight.135544 Perkhofer, 2018, Importance of organoids for personalized medicine, Person Med, 15, 461, 10.2217/pme-2018-0071 Clevers, 2020, COVID-19: organoids go viral, Nat Rev Mol Cell Biol, 21, 355, 10.1038/s41580-020-0258-4 Sato, 2009, Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche, Nature, 459, 262, 10.1038/nature07935 Spence, 2011, Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro, Nature, 470, 105, 10.1038/nature09691 Holloway, 2020, Differentiation of human intestinal organoids with endogenous vascular endothelial cells, Dev Cell, 54, 516, 10.1016/j.devcel.2020.07.023 Lamers, 2020, SARS-CoV-2 productively infects human gut enterocytes, Science, 369, 50, 10.1126/science.abc1669 Zang, 2020, TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes, Sci Immunol, 5, 10.1126/sciimmunol.abc3582 Stanifer, 2020, Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells, Cell Rep, 32, 107863, 10.1016/j.celrep.2020.107863 Zhou, 2020, Infection of bat and human intestinal organoids by SARS-CoV-2, Nat Med, 26, 1077, 10.1038/s41591-020-0912-6 Li, 2020, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat Rev Drug Discov, 19, 149, 10.1038/d41573-020-00016-0 Beigel, 2020, Remdesivir for the treatment of Covid-19 - preliminary report, N Engl J Med, 383, 1813, 10.1056/NEJMoa2007764 Freedberg, 2020, Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study, Gastroenterology, 159, 1129, 10.1053/j.gastro.2020.05.053 Sethia Ortega, 2020, Class A G protein-coupled receptor antagonist famotidine as a therapeutic alternative against SARS-CoV2: an in silico analysis, Biomolecules, 10, 954, 10.3390/biom10060954 Janowitz, 2020, Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series, Gut, 69, 1592, 10.1136/gutjnl-2020-321852 Cortez, 2020, Astrovirus infects actively secreting goblet cells and alters the gut mucus barrier, Nature Communications, 11, 2097, 10.1038/s41467-020-15999-y Xia, 2019, A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike, Sci Adv, 5, eaav4580, 10.1126/sciadv.aav4580 Conzelmann, 2020, An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection, Antiviral Res, 181, 104882, 10.1016/j.antiviral.2020.104882 Hassan, 2020, A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2, Cell, 183, 169, 10.1016/j.cell.2020.08.026 Ramos da Silva Pan Hahm, 1995, Comparison of immunomodulative effects of the histamine-2 receptor antagonists cimetidine, ranitidine, and famotidine on peripheral blood mononuclear cells in gastric cancer patients, Scand J Gastroenterol, 30, 265, 10.3109/00365529509093275 Morichika, 2003, Histamine inhibits lipopolysaccharide-induced tumor necrosis factor-α production in an intercellular adhesion molecule-1-and B7. 1-dependent manner, J Pharmacol Exp Ther, 304, 624, 10.1124/jpet.102.042515 Smolinska, 2016, Histamine receptor 2 is required to suppress innate immune responses to bacterial ligands in patients with inflammatory bowel disease, Inflamm Bowel Dis, 22, 1575, 10.1097/MIB.0000000000000825 Fischer, 2020, Human peptide alpha-defensin-1 interferes with Clostridioides difficile toxins TcdA, TcdB, and CDT, FASEB J, 34, 6244, 10.1096/fj.201902816R di Masi, 2018, Human serum albumin is an essential component of the host defense mechanism against Clostridium difficile intoxication, J Infect Dis, 218, 1424, 10.1093/infdis/jiy338 Ernst, 2017, Hsp70 facilitates trans-membrane transport of bacterial ADP-ribosylating toxins into the cytosol of mammalian cells, Sci Rep, 7, 2724, 10.1038/s41598-017-02882-y Chu, 2020, Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia, Clin Chem, 66, 549, 10.1093/clinchem/hvaa029 Groß, 2020, Detection of SARS-CoV-2 in human breast milk, Lancet, 395, 1757, 10.1016/S0140-6736(20)31181-8 Reed, 1938, A simple method of estimating fifty per cent endpoints12, Am J Epidemiol, 27, 493, 10.1093/oxfordjournals.aje.a118408